An ambispective, observational real-world study of tumor-treating fields for treatment of Chinese patients with newly diagnosed or recurrent/progressive glioblastoma
Year: 2026
Type: article
Study design: Observational Study
Abstract: Background: Glioblastoma is the most common and aggressive central nervous system malignancy with poor prognosis. Tumor-treating fields (TTFields), approved in China in May 2020, represents a significant advancement in GBM treatment. Leveraging the extensive real-world data accumulated in the Chinese Medical Information and Big Data Association (CHMIA) database, this study aims to assess clinical outcomes of Chinese patients with glioblastoma on TTFields therapy. Methods: This ambispective, observational study assessed post-marketing safety (data cut-off: November 15, 2021) and effectiveness (data cut-off: May 18, 2024) of TTFields in Chinese patients with newly diagnosed glioblastoma (ndGBM) and recurrent glioblastoma (rGBM). Safety outcomes included incidence and severity of skin adverse events (AEs); effectiveness was measured by overall survival (OS) and landmark OS rates. Results: = 105). In the ndGBM cohort, the median OS was 19.9 months (95% CI: 13.4-24.8), with a 12-month OS rate of 63.5% (95% CI: 54.8-71.0). In the rGBM cohort, the median OS was 8.1 months (95% CI: 5.3-9.8), and 3-month and 6-month OS rates were 80.2% (95% CI: 70.4-87.1) and 58.7% (95% CI: 47.0-68.7), respectively. Most treatment-emergent AEs (TEAEs), including skin TEAEs, were mild to moderate (Grade 1-2). Conclusions: This study provided the largest real-world dataset to-date on TTFields in Chinese patients with glioblastoma. These patients showed survival outcomes similar to those in prior pivotal studies, without new safety concerns identified, supporting its use in Chinese glioblastoma population.
Source: Neuro-Oncology Advances
Authors: Guanzhang Li, Xiaoguang Qiu, Wei Zhang, Man Hu, Zhiyong Qin, Yang Wang, Jinsong Wu, Wenjie Guo, Xia He, Yongping You, Junxia Zhang, Guanglong Huang, Songtao Qi, Wenbin Ma, Yu Wang, Gang Li, Hua Feng, Fei Li, Yuanyuan Chen, Yonggao Mou, Zhong Wang, Fuyi Liu, Chun Wang, Guangyuan Hu, Kai Shu, Yanhui Liu, Qing Mao, Xiang Wang, Yuan Yang, Juan Dong, Jianmei Hou, Jiayu Fu, Ruijun Xing, Xiang Li, Jun Wan, Hui Zhu, Xuejun Yang, Tao Jiang
Institutions: Capital Medical University, Beijing Tian Tan Hospital, Qilu Hospital of Shandong University, Beijing Institute for Brain Disorders, Shandong First Medical University, Fudan University, Huashan Hospital, Peking Union Medical College Hospital, Jiangsu Cancer Hospital, Jiangsu Province Hospital, Nanfang Hospital, Southern Medical University, Army Medical University, Southwest Hospital, Sun Yat-sen University Cancer Center, First Affiliated Hospital of Soochow University, Second Affiliated Hospital of Zhejiang University, Zhejiang University, Tongji Hospital, Huazhong University of Science and Technology, Sichuan University, West China Hospital of Sichuan University, Beijing Tsinghua Chang Gung Hospital, Tsinghua University
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,615
OpenAlex ID: W7160211634